Nomogram to predict primary non-response to infliximab in patients with Crohn's disease: a multicenter study
{{output}}
Background: Infliximab (IFX) is effective at inducing and maintaining clinical remission and mucosal healing in patients with Crohn's disease (CD); however, 9%-40% of patients do not respond to primary IFX treatment. This study a... ...
